|Agreement labeling||Thieme 2022-23 Journals Transitional OA Agreement (SMP)|
|Has the agreement been fully disclosed and published?||Yes|
|Agreement period||01/01/2022 – 12/31/2023|
|Consortia / Institution||Jisc|
Approximate range of annual corresponding author publications
|Comments on size/article output||Articles 2019/20 average of the participants at the time. Increased uptake for 2022 by Inst.|
How do the costs of the agreement relate to previous subscription-only agreements with the publisher?
|Agreement costs within the range of the previous spending level|
Transfomative agreements vary by their transformative mechanisms, meaning the way in which financing is shifted from the subscription side to open access publishing. What are the characteristics of this agreement to this regard?
|Subscriptions partly converted to OA publishing fees|
How do entitlements for open access publishing correlate to the anticipated article output? Which mechanisms for risk sharing have been agreed in cases of exceeding or not reaching the number of OA publishing entitlements?
|Unlimited OA. Requires author to opt-in to OA publishing, workflow improvements made.|
Are all journals relevant to your affiliated authors (in which you expect them to publish) eligible for OA publishing under the agreement?
|Are fully open access journals covered by the agreement?||No|
|OA LICENSE||CC-BY mandatory|
||Original research articles
What is the approximate share of access related costs of the overall agreement?
|More than 50%|
Are all read relevant journals covered by the agreement?
|PERPETUAL ACCESS RIGHTS||Yes|
|WORKFLOW ASSESSMENT||Too early to assess|
|Comments on workflows||Thieme has improved the workflow within 2021. We will assess the impact of these changes.|
|OVERALL ASSESSMENT AND COMMENTS||This agreement transitions aims to convert an improved (following workflow updates in 2021) and significant proportion of UK research publishing output towards open access within the bespoke collection of Medical and Chemistry titles, for an acceptable increase over previous spend. The efficacy of the agreement will be reviewed by Jisc throughout its term.|
|Request contact to the licensee||contact [at] esac-initiative [dot] org|